EAVI2020
EUROPEAN AIDS VACCINE INITIATIVE

European Commission

Project summary:

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, human vaccine studies to select and refine the best vaccine candidates for advanced development, and will determine the impact of host factors such as gender and genetics on vaccine induced immunity. Pre-clinical models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the “risk curve” in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.

List of partners

No	Name	Country
1	Imperial College, London	United Kingdom
2	University of Oxford	United Kingdom
3	Institut National de Santé et de Recherche Médicale	France
4	Fundació Privada Institut de Recerca de la Sida-Caixa	Spain
5	Istituto Superiore di Sanita	Italy
6	Polymun Scientific Immunbiologische Forcshung GmbH	Austria
7	Fundació Privada Clínic per a la Recerca Biomèdica	Spain
8	Academisch Medisch Centrum	Netherlands
9	Comissariat a l'energie atomique et aux energies alternatives	France
10	Ospedale San Raffaele	Italy
11	University Joseph Fourier Grenoble	France
12	King's College London	United Kingdom
13	Karolinska Institutet	Sweden
14	Universitätsklinikum Erlangen	Germany
15	The University of Western Ontario	Canada
16	Nemzeti Elelmiszerlanc-biztonsagi Hivatal	Hungary
17	Ludwig Boltzmann Institute	Austria
18	BioNTech RNA Pharmaceuticals	Germany

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681137

19	Instituto de Salud Carlos III	Spain
20	Stitching International AIDS Vaccine Initiative	Netherlands
21	University of Melbourne	Australia
22	University of New South Wales	Australia
23	Genome Research Limited (Sanger Institute)	United Kingdom

EAVI2020 participants



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681137

EAVI2020 Non-EU participants



Follow us:

@EAVI2020

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681137